Advances in understanding of mechanisms related to increased cardiovascular risk in COPD

References

• Foreman KJ, Marquez N, Dolgert A, et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016–40 for 195 countries and territories. Lancet. 2018;392(10159):2052–2090.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Calzetta L, Bettoncelli G, et al. Cardiovascular disease in asthma and COPD: a population-based retrospective cross-sectional study. Respir Med. 2012;106(2):249–256.
   PubMed Web of Science ®Google Scholar
• Rabe KF, Hurst JR, Suissa S. Cardiovascular disease and COPD: dangerous liaisons? Eur Respir Rev. 2018;27(149):180057.
   PubMed Web of Science ®Google Scholar
• Calzetta L, Orlandi A, Page C, et al. Brain natriuretic peptide: much more than a biomarker. Int J Cardiol. 2016;221:1031–1038.
   PubMed Web of Science ®Google Scholar
• Arnett DK, Goodman RA, Halperin JL, et al. AHA/ACC/HHS strategies to enhance application of clinical practice guidelines in patients with cardiovascular disease and comorbid conditions: from the American heart association, American college of cardiology, and US department of health and human services. Circulation. 2014;130(18):1662–1667.
   PubMed Web of Science ®Google Scholar
• Soriano JB, Rigo F, Guerrero D, et al. High prevalence of undiagnosed airflow limitation in patients with cardiovascular disease. Chest. 2010;137(2):333–340.
   PubMed Web of Science ®Google Scholar
• Anthonisen NR, Skeans MA, Wise RA, et al. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med. 2005;142(4):233–239.
   PubMed Web of Science ®Google Scholar
• Calverley PMA, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775–789.
   PubMed Web of Science ®Google Scholar
• Kahnert K, Alter P, Young D, et al. The revised GOLD 2017 COPD categorization in relation to comorbidities. Respir Med. 2018;134:79–85.
   PubMed Web of Science ®Google Scholar
• GOLD. Global initiative for chronic obstructive lung disease. Global strategy for diagnosis, management, and prevention of COPD – 2020 Report. 2020 [cited 2020 Sept 4]. Available from https://goldcopd.org/wp-content/uploads/2019/12/GOLD-2020-FINAL-ver1.2-03Dec19_WMV.pdf
   Google Scholar
• Sin DD, Wu L, Man SF. The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature. Chest. 2005;127(6):1952–1959.
   PubMed Web of Science ®Google Scholar
• Rogliani P, Cazzola M, Calzetta L. Cardiovascular disease in chronic respiratory disorders and beyond. J Am Coll Cardiol. 2019;73(17):2178–2180.
   PubMed Web of Science ®Google Scholar
• Smith MC, Wrobel JP. Epidemiology and clinical impact of major comorbidities in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2014;9:871–888.
   PubMed Web of Science ®Google Scholar
• Lange P, Celli B, Agustí A, et al. Lung-function trajectories leading to chronic obstructive pulmonary disease. N Engl J Med. 2015;373(2):111–122.
   PubMed Web of Science ®Google Scholar
• Bui DS, Lodge CJ, Burgess JA, et al. Childhood predictors of lung function trajectories and future COPD risk: a prospective cohort study from the first to the sixth decade of life. Lancet Respir Med. 2018;6(7):535–544.
   PubMed Web of Science ®Google Scholar
• Agusti A, Faner R. Lung function trajectories in health and disease. Lancet Respir Med. 2019;7(4):358–364.
   PubMed Web of Science ®Google Scholar
• Chen W, Thomas J, Sadatsafavi M, et al. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respir Med. 2015;3(8): 631–639.
   PubMed Web of Science ®Google Scholar
• Morgan AD, Zakeri R, Quint JK. Defining the relationship between COPD and CVD: what are the implications for clinical practice? Ther Adv Respir Dis. 2018;12:1753465817750524.
   Web of Science ®Google Scholar
• Baty F, Putora PM, Isenring B, et al. Comorbidities and burden of COPD: a population based case-control study. PloS One. 2013;8(5):e63285.
   PubMed Web of Science ®Google Scholar
• Roversi S, Fabbri LM, Sin DD, et al. Chronic obstructive pulmonary disease and cardiac diseases. an urgent need for integrated care. Am J Respir Crit Care Med. 2016;194(11):1319–1336.
   PubMed Web of Science ®Google Scholar
• Mullerova H, Agusti A, Erqou S, et al. Cardiovascular comorbidity in COPD: systematic literature review. Chest. 2013;144(4):1163–1178.
   PubMed Web of Science ®Google Scholar
• Roth GA, Abate D, Abate KH, et al. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1736–1788.
   PubMed Web of Science ®Google Scholar
• Patel ARC, Donaldson GC, Mackay AJ, et al. The impact of ischemic heart disease on symptoms, health status, and exacerbations in patients with COPD. Chest. 2012;141(4):851–857.
   PubMed Web of Science ®Google Scholar
• Mentz RJ, Kelly JP, von Lueder TG, et al. Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction. J Am Coll Cardiol. 2014;64(21):2281–2293.
   PubMed Web of Science ®Google Scholar
• Kwon BJ, Kim DB, Jang SW, et al. Prognosis of heart failure patients with reduced and preserved ejection fraction and coexistent chronic obstructive pulmonary disease. Eur J Heart Fail. 2010;12(12):1339–1344.
   PubMed Web of Science ®Google Scholar
• Higashimoto Y, Yamagata T, Maeda K, et al. Influence of comorbidities on the efficacy of pulmonary rehabilitation in patients with chronic obstructive pulmonary disease. Geriatr Gerontol Int. 2016;16(8):934–941.
   PubMed Web of Science ®Google Scholar
• Battaglia S, Basile M, Scichilone N, et al. Prevalence of Co-morbidities and Severity of COPD. Copd. 2015;12(4):390–394.
   PubMedGoogle Scholar
• Konecny T, Park JY, Somers KR, et al. Relation of chronic obstructive pulmonary disease to atrial and ventricular arrhythmias. Am J Cardiol. 2014;114(2):272–277.
   PubMed Web of Science ®Google Scholar
• Yin L, Lensmar C, Ingelsson E, et al. Differential association of chronic obstructive pulmonary disease with myocardial infarction and ischemic stroke in a nation-wide cohort. Int J Cardiol. 2014;173(3):601–603.
   PubMed Web of Science ®Google Scholar
• MacDonald MI, Shafuddin E, King PT, et al. Cardiac dysfunction during exacerbations of chronic obstructive pulmonary disease. Lancet Respir Med. 2016;4(2):138–148.
   PubMed Web of Science ®Google Scholar
• Rothnie KJ, Smeeth L, Herrett E, et al. Closing the mortality gap after a myocardial infarction in people with and without chronic obstructive pulmonary disease. Heart. 2015;101(14):1103–1110.
   PubMed Web of Science ®Google Scholar
• Sidney S, Sorel M, Quesenberry CP Jr., et al. COPD and incident cardiovascular disease hospitalizations and mortality: kaiser Permanente Medical Care Program. Chest. 2005;128(4):2068–2075.
   PubMed Web of Science ®Google Scholar
• Houben-Wilke S, Jorres RA, Bals R, et al. Peripheral artery disease and its clinical relevance in patients with chronic obstructive pulmonary disease in the copd and systemic consequences-comorbidities network study. Am J Respir Crit Care Med. 2017;195(2):189–197.
   PubMed Web of Science ®Google Scholar
• Campo G, Pavasini R, Barbetta C, et al. Predischarge screening for chronic obstructive pulmonary disease in patients with acute coronary syndrome and smoking history. Int J Cardiol. 2016;222:806–812.
   PubMed Web of Science ®Google Scholar
• Portegies ML, Lahousse L, Joos GF, et al. Chronic Obstructive Pulmonary Disease and the Risk of Stroke. The Rotterdam Study. Am J Respir Crit Care Med. 2016;193(3):251–258.
   PubMed Web of Science ®Google Scholar
• Campo G, Pavasini R, Malagu M, et al. Chronic obstructive pulmonary disease and ischemic heart disease comorbidity: overview of mechanisms and clinical management. Cardiovasc Drugs Ther. 2015;29(2):147–157.
   PubMed Web of Science ®Google Scholar
• Sin DD, Man SFP. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation. 2003;107(11):1514–1519.
   PubMed Web of Science ®Google Scholar
• Castaldi PJ, Benet M, Petersen H, et al. Do COPD subtypes really exist? COPD heterogeneity and clustering in 10 independent cohorts. Thorax. 2017;72(11):998–1006.
   PubMed Web of Science ®Google Scholar
• Garcia-Aymerich J, Gómez FP, Benet M, et al. Identification and prospective validation of clinically relevant chronic obstructive pulmonary disease (COPD) subtypes. Thorax. 2011;66(5):430–437.
   PubMed Web of Science ®Google Scholar
• Vanfleteren LEGW, Spruit MA, Groenen M, et al. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;187(7):728–735.
   PubMed Web of Science ®Google Scholar
• Boschetto P, Beghe B, Fabbri LM, et al. Link between chronic obstructive pulmonary disease and coronary artery disease: implication for clinical practice. Respirology. 2012;17(3):422–431.
   PubMed Web of Science ®Google Scholar
• Vivodtzev I, Tamisier R, Baguet JP, et al. Arterial stiffness in COPD. Chest. 2014;145(4):861–875.
   PubMed Web of Science ®Google Scholar
• Vogelmeier C, Bals R. Chronic obstructive pulmonary disease and premature aging. American Journal of Respiratory and Critical Care Medicine; 2007; 175(12):1217–8
   PubMed Web of Science ®Google Scholar
• Vivodtzev I, Tamisier R, Baguet J-P, et al. Arterial stiffness in COPD. Chest. 2014;145(4):861–875.
   PubMed Web of Science ®Google Scholar
• Jia G, Aroor AR, Jia C, et al. Endothelial cell senescence in aging-related vascular dysfunction. Biochim Biophys Acta Mol Basis Dis. 2019;1865(7):1802–1809.
   PubMed Web of Science ®Google Scholar
• Maclay JD, MacNee W. Cardiovascular disease in COPD: mechanisms. Chest. 2013;143(3):798–807.
   PubMed Web of Science ®Google Scholar
• Vanfleteren LEGW, Spruit MA, Groenen MTJ, et al. Arterial stiffness in patients with COPD: the role of systemic inflammation and the effects of pulmonary rehabilitation. Eur Respir J. 2014;43(5):1306–1315.
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Senescence in COPD and its comorbidities. Annu Rev Physiol. 2017;79:517–539.
   PubMed Web of Science ®Google Scholar
• Minamino T, Miyauchi H, Yoshida T, et al. Endothelial cell senescence in human atherosclerosis: role of telomere in endothelial dysfunction. Circulation. 2002;105(13):1541–1544.
   PubMed Web of Science ®Google Scholar
• Lattimore J-DL, Wilcox I, Nakhla S, et al. Repetitive hypoxia increases lipid loading in human macrophages—a potentially atherogenic effect. Atherosclerosis. 2005;179(2):255–259.
   PubMed Web of Science ®Google Scholar
• Watz H, Waschki B, Meyer T, et al. Decreasing cardiac chamber sizes and associated heart dysfunction in COPD: role of hyperinflation. Chest. 2010;138(1):32–38.
   PubMed Web of Science ®Google Scholar
• Smith BM, Prince MR, Hoffman EA, et al. Impaired left ventricular filling in COPD and emphysema: is it the heart or the lungs? The multi-ethnic study of atherosclerosis COPD study. Chest. 2013;144(4):1143–1151.
   PubMed Web of Science ®Google Scholar
• Ferguson GT. Why does the lung hyperinflate? Proc Am Thorac Soc. 2006;3(2):176–179.
   PubMedGoogle Scholar
• Zangiabadi A, De Pasquale CG, Sajkov D. Pulmonary hypertension and right heart dysfunction in chronic lung disease. Biomed Res Int. 2014;2014:739674.
   PubMed Web of Science ®Google Scholar
• Vonk-Noordegraaf A. The shrinking heart in chronic obstructive pulmonary disease. New England Journal of Medicine; 2010;362(3):267–8
   PubMed Web of Science ®Google Scholar
• Campo G, Guastaroba P, Marzocchi A, et al. Impact of COPD on long-term outcome after ST-segment elevation myocardial infarction receiving primary percutaneous coronary intervention. Chest. 2013;144(3):750–757.
   PubMed Web of Science ®Google Scholar
• Pavasini R, D’ Ascenzo F, Campo G, et al. Cardiac troponin elevation predicts all-cause mortality in patients with acute exacerbation of chronic obstructive pulmonary disease: systematic review and meta-analysis. Int J Cardiol. 2015;191:187–193.
   PubMed Web of Science ®Google Scholar
• Gan WQ, Man SF, Senthilselvan A, et al. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax. 2004;59(7):574–580.
   PubMed Web of Science ®Google Scholar
• Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J. 2009;33(5):1165–1185.
   PubMed Web of Science ®Google Scholar
• Gomez-Cabrero D, Lluch-Ariet M, Tegnér J, et al. Synergy-COPD: a systems approach for understanding and managing chronic diseases. J Transl Med. 2014;12(Suppl 2):S2
   PubMedGoogle Scholar
• Miralles F, Gomez-Cabrero D, Lluch-Ariet M, et al. Predictive medicine: outcomes, challenges and opportunities in the Synergy-COPD project. J Transl Med. 2014;12(2):1–8.
   PubMedGoogle Scholar
• Mannino DM, Thorn D, Swensen A, et al. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J. 2008;32(4):962–969.
   PubMed Web of Science ®Google Scholar
• Sinden NJ, Stockley RA. Systemic inflammation and comorbidity in COPD: a result of ‘overspill’ of inflammatory mediators from the lungs? Review of the evidence. Thorax. 2010;65(10):930–936.
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Chronic obstructive pulmonary disease: effects beyond the lungs. PLoS Med. 2010;7(3):e1000220.
   PubMed Web of Science ®Google Scholar
• Vernooy JH, Kucukaycan M, Jacobs JA, et al. Local and systemic inflammation in patients with chronic obstructive pulmonary disease: soluble tumor necrosis factor receptors are increased in sputum. Am J Respir Crit Care Med. 2002;166(9): 1218–1224.
   PubMed Web of Science ®Google Scholar
• Sapey E, Ahmad A, Bayley D, et al. Imbalances between interleukin-1 and tumor necrosis factor agonists and antagonists in stable COPD. J Clin Immunol. 2009;29(4):508–516.
   PubMed Web of Science ®Google Scholar
• Nemmar A, Hoylaerts MF, Hoet PH, et al. Possible mechanisms of the cardiovascular effects of inhaled particles: systemic translocation and prothrombotic effects. Toxicol Lett. 2004;149(1–3):243–253.
   PubMed Web of Science ®Google Scholar
• Agusti A, Soriano JB. COPD as a systemic disease. Copd. 2008;5(2):133–138.
   PubMedGoogle Scholar
• Watz H, Waschki B, Kirsten A, et al. The metabolic syndrome in patients with chronic bronchitis and COPD: frequency and associated consequences for systemic inflammation and physical inactivity. Chest. 2009;136(4):1039–1046.
   PubMed Web of Science ®Google Scholar
• Tkacova R, Systemic Inflammation in Chronic Obstructive Pulmonary Disease: May Adipose Tissue Play a Role? Review of the Literature and Future Perspectives. Mediators Inflamm. 2010;2010:585989
   PubMed Web of Science ®Google Scholar
• Ouchi N, Parker JL, Lugus JJ, et al. Adipokines in inflammation and metabolic disease. Nat Rev Immunol. 2011;11(2):85–97.
   PubMed Web of Science ®Google Scholar
• Miller J, Edwards LD, Agusti A, et al. Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. Respir Med. 2013;107(9):1376–1384.
   PubMed Web of Science ®Google Scholar
• Williams MC, Murchison JT, Edwards LD, et al. Coronary artery calcification is increased in patients with COPD and associated with increased morbidity and mortality. Thorax. 2014;69(8):718–723.
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Seemungal TAR. COPD exacerbations: defining their cause and prevention. Lancet. 2007;370(9589):786–796.
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Brill SE, Allinson JP, et al. Mechanisms and impact of the frequent exacerbator phenotype in chronic obstructive pulmonary disease. BMC Med. 2013;11(1):181.
   PubMedGoogle Scholar
• Halpin DMG, Decramer M, Celli B, et al. Risk of nonlower respiratory serious adverse events following COPD exacerbations in the 4-year UPLIFT® trial. Lung. 2011;189(4):261–268.
   PubMed Web of Science ®Google Scholar
• Harrison MT, Short P, Williamson PA, et al. Thrombocytosis is associated with increased short and long term mortality after exacerbation of chronic obstructive pulmonary disease: a role for antiplatelet therapy? Thorax. 2014;69(7):609–615.
   PubMed Web of Science ®Google Scholar
• Donaldson GC, Seemungal TA, Patel IS, et al. Airway and systemic inflammation and decline in lung function in patients with COPD. Chest. 2005;128(4):1995–2004.
   PubMed Web of Science ®Google Scholar
• Chang CL, Robinson SC, Mills GD, et al. Biochemical markers of cardiac dysfunction predict mortality in acute exacerbations of COPD. Thorax. 2011;66(9):764–768.
   PubMed Web of Science ®Google Scholar
• Mahajan N, Mehta Y, Rose M, et al. Elevated troponin level is not synonymous with myocardial infarction. Chest. 2005;128(4):166S.
   Web of Science ®Google Scholar
• Harvey MG, Hancox RJ. Elevation of cardiac troponins in exacerbation of chronic obstructive pulmonary disease. Emergency Medicine Australasia. 2004;16(3):212–215.
   PubMedGoogle Scholar
• Daniels LB, Maisel AS. Natriuretic peptides. J Am Coll Cardiol. 2007;50(25):2357–2368.
   PubMed Web of Science ®Google Scholar
• Wang TJ, Larson MG, Levy D, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med. 2004;350(7):655–663.
   PubMed Web of Science ®Google Scholar
• Marcun R, Sustic A, Brguljan PM, et al. Cardiac biomarkers predict outcome after hospitalisation for an acute exacerbation of chronic obstructive pulmonary disease. Int J Cardiol. 2012;161(3): 156–159.
   PubMed Web of Science ®Google Scholar
• Donaldson GC, Hurst JR, Smith CJ, et al. Increased risk of myocardial infarction and stroke following exacerbation of COPD. Chest. 2010;137(5):1091–1097.
   PubMed Web of Science ®Google Scholar
• Zagaceta J, Bastarrika G, Zulueta JJ, et al. Prospective comparison of non-invasive risk markers of major cardiovascular events in COPD patients. Respir Res. 2017;18(1):175.
   PubMedGoogle Scholar
• Pavasini R, Tavazzi G, Biscaglia S, et al. Amino terminal pro brain natriuretic peptide predicts all-cause mortality in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis. Chron Respir Dis. 2017;14(2):117–126.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Calzetta L, Matera MG, et al. Chronic obstructive pulmonary disease and coronary disease: cOPDCoRi, a simple and effective algorithm for predicting the risk of coronary artery disease in COPD patients. Respir Med. 2015;109(8): 1019–1025.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Rogliani P, Matera MG. Cardiovascular disease in patients with COPD. Lancet Respir Med. 2015;3(8):593–595.
   PubMed Web of Science ®Google Scholar
• Skinner JS, Smeeth L, Kendall JM, et al. NICE guidance. Chest pain of recent onset: assessment and diagnosis of recent onset chest pain or discomfort of suspected cardiac origin. Heart. 2010;96(12):974–978.
   PubMed Web of Science ®Google Scholar
• Bhatt SP, Kazerooni EA, Newell JD Jr., et al. Visual estimate of coronary artery calcium predicts cardiovascular disease in COPD. Chest. 2018;154(3): 579–587.
   PubMed Web of Science ®Google Scholar
• Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol. 2010;55(13):1318–1327.
   PubMed Web of Science ®Google Scholar
• Ferrara N. Molecular and biological properties of vascular endothelial growth factor. J Mol Med. 1999;77(7):527–543.
   PubMed Web of Science ®Google Scholar
• Soeki T, Tamura Y, Shinohara H, et al. Serial changes in serum VEGF and HGF in patients with acute myocardial infarction. Cardiology. 2000;93(3):168–174.
   PubMed Web of Science ®Google Scholar
• Valipour A, Schreder M, Wolzt M, et al. Circulating vascular endothelial growth factor and systemic inflammatory markers in patients with stable and exacerbated chronic obstructive pulmonary disease. Clin Sci. 2008;115(7):225–232.
   PubMed Web of Science ®Google Scholar
• Kohara K, Tabara Y, Tachibana R, et al. Microalbuminuria and arterial stiffness in a general population: the Shimanami Health Promoting Program (J-SHIPP) study. Hypertens Res. 2004;27(7):471–477.
   PubMed Web of Science ®Google Scholar
• Romundstad S, Holmen J, Kvenild K, et al. Microalbuminuria and all-cause mortality in 2,089 apparently healthy individuals: a 4.4-year follow-up study. The nord-Trøndelag health study (HUNT), Norway. Am J Kidney Diseases. 2003;42(3):466–473.
   PubMed Web of Science ®Google Scholar
• Wang J-G, Staessen JA, Li Y, et al. Carotid intima-media thickness and antihypertensive treatment: a meta-analysis of randomized controlled trials. Stroke. 2006;37(7):1933–1940.
   PubMed Web of Science ®Google Scholar
• Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction: testing and clinical relevance. Circulation. 2007;115(10):1285–1295.
   PubMed Web of Science ®Google Scholar
• Mohan D, Forman JR, Allinder M, et al. Fibrinogen does not relate to cardiovascular or muscle manifestations in COPD: cross-sectional data from the ERICA study. Thorax. 2018;73(12):1182–1185.
   PubMed Web of Science ®Google Scholar
• Gabay C, Kushner I, Epstein FH. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340(6):448–454.
   PubMed Web of Science ®Google Scholar
• Ghoorah K, De Soyza A, Kunadian V. Increased cardiovascular risk in patients with chronic obstructive pulmonary disease and the potential mechanisms linking the two conditions: a review. Cardiol Rev. 2013;21(4):196–202.
   PubMed Web of Science ®Google Scholar
• Leuzzi G, Galeone C, Taverna F, et al. C-reactive protein level predicts mortality in COPD: a systematic review and meta-analysis. Eur Respir Rev. 2017;26(143):160070.
   PubMed Web of Science ®Google Scholar
• de Vos LC, Mulder DJ, Smit AJ, et al. Skin autofluorescence is associated with 5-year mortality and cardiovascular events in patients with peripheral artery disease. Arterioscler Thromb Vasc Biol. 2014;34(4):933–938.
   PubMed Web of Science ®Google Scholar
• Wilson PW, D’Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97(18):1837–1847.
   PubMed Web of Science ®Google Scholar
• Sin DD, Wu L, Man SFP. The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature. Chest. 2005;127(6):1952–1959.
   PubMed Web of Science ®Google Scholar
• Brekke PH, Omland T, Smith P, et al. Underdiagnosis of myocardial infarction in COPD–Cardiac Infarction Injury Score (CIIS) in patients hospitalised for COPD exacerbation. Respir Med. 2008;102(9):1243–1247.
   PubMed Web of Science ®Google Scholar
• Cinarka H, Kayhan S, Gumus A, et al. Arterial stiffness measured via carotid femoral pulse wave velocity is associated with disease severity in COPD. Respir Care. 2014;59(2):274–280.
   PubMed Web of Science ®Google Scholar
• Ahluwalia A, MacAllister RJ, Hobbs AJ. Vascular actions of natriuretic peptides - Cyclic GMP-dependent and -independent mechanisms [Review]. Basic Res Cardiol. 2004;99(2):83–89.
   PubMed Web of Science ®Google Scholar
• Matera MG, Calzetta L, Passeri D, et al. Epithelium integrity is crucial for the relaxant activity of brain natriuretic peptide in human isolated bronchi. Br J Pharmacol. 2011;163(8):1740–1754.
   PubMed Web of Science ®Google Scholar
• Calzetta L, Passeri D, Kanabar V, et al. Brain natriuretic peptide protects against hyperresponsiveness of human asthmatic airway smooth muscle via an epithelial cell-dependent mechanism. Am J Respir Cell Mol Biol. 2014;50(3):493–501.
   PubMed Web of Science ®Google Scholar
• Akerman MJ, Yaegashi M, Khiangte Z, et al. Bronchodilator effect of infused B-type natriuretic peptide in asthma. Chest. 2006;130(1):66–72.
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the european society of cardiology. developed in collaboration with the heart failure association (HFA) of the ESC. Eur Heart J. 2012;33(14):1787–1847.
   PubMed Web of Science ®Google Scholar
• Andersen CU, Mellemkjaer S, Nielsen-Kudsk JE, et al. Echocardiographic screening for pulmonary hypertension in stable COPD out-patients and NT-proBNP as a rule-out test. Copd. 2012;9(5):505–512.
   PubMedGoogle Scholar
• Yap LB, Mukerjee D, Timms PM, et al. Natriuretic peptides, respiratory disease, and the right heart. Chest. 2004;126(4):1330–1336.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Matera MG. B-type natriuretic peptide—not only a biomarker. Eur Respir Dis. 2011;7:80–82.
   Google Scholar
• Gariani K, Delabays A, Perneger TV, et al. Use of brain natriuretic peptide to detect previously unknown left ventricular dysfunction in patients with acute exacerbation of chronic obstructive pulmonary disease. Swiss Med Wkly. 2011;141:w13298.
   PubMed Web of Science ®Google Scholar
• Berger JS, Sanborn TA, Sherman W, et al. Effect of chronic obstructive pulmonary disease on survival of patients with coronary heart disease having percutaneous coronary intervention. Am J Cardiol. 2004;94(5):649–651.
   PubMed Web of Science ®Google Scholar
• NICE. National institute for health and care excellence. multimorbidity: clinical assessment and management. NICE guideline [NG56]. 2016 [cited 2020 Oct 14]. Available from: https://www.nice.org.uk/guidance/ng56
   Google Scholar